



ASX ANNOUNCEMENT

August 13, 2024

Chimeric receives \$1.5 M advance on FY24 R&D tax incentive

Sydney, Australia, 13 August 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce it has received \$1,562,000 from Endpoints Capital under a funding facility secured against Chimeric’s anticipated FY24 Research and Development Tax Incentive (RDTI).

The funds will support the clinical trial pipeline and otherwise for general working capital of the Company.

The funding agreement with Endpoints Capital provides Chimeric with early access to a portion of the Company’s anticipated FY24 RDTI. The facility is secured against the anticipated FY24 RDTI to be received from the Australian Taxation Office, with interest charged at a commercial rate. Repayment is timed to follow the anticipated receipt of the Company’s FY24 RDTI, and is due by 31 December 2024. The facility can be repaid at any time without penalty prior to this date. The Australian Government RDTI program provides companies engaging in eligible activities with a refundable tax offset of up to 43.5%.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer.

To bring that promise to life for more patients, Chimeric’s world class team of cell therapy pioneers is focused on the discovery, development, and commercialisation of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of



cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CLTX is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CLTX CAR T is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

ABOUT ENDPOINTS CAPITAL

Endpoints Capital is a market leading Australian R&D finance firm that specialises in finance solutions for biotechnology companies accessing the Australian research and development tax incentive scheme. Endpoints Capital is backed by an Australian family office with significant experience investing in Australia's life sciences industry.